Logo image of ADN

ADVENT TECHNOLOGIES HOLDINGS (ADN) Stock Fundamental Analysis

NASDAQ:ADN - Nasdaq - US00788A2042 - Common Stock - Currency: USD

4.96  -0.14 (-2.75%)

After market: 4.97 +0.01 (+0.2%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADN. ADN was compared to 93 industry peers in the Electrical Equipment industry. Both the profitability and financial health of ADN have multiple concerns. ADN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ADN had negative earnings in the past year.
In the past year ADN has reported a negative cash flow from operations.
ADN had negative earnings in each of the past 5 years.
In the past 5 years ADN always reported negative operating cash flow.
ADN Yearly Net Income VS EBIT VS OCF VS FCFADN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

ADN's Return On Assets of -885.29% is on the low side compared to the rest of the industry. ADN is outperformed by 97.83% of its industry peers.
Industry RankSector Rank
ROA -885.29%
ROE N/A
ROIC N/A
ROA(3y)-100.37%
ROA(5y)-96.93%
ROE(3y)-220.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADN Yearly ROA, ROE, ROICADN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADN Yearly Profit, Operating, Gross MarginsADN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -500 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ADN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADN has more shares outstanding
Compared to 5 years ago, ADN has more shares outstanding
ADN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADN Yearly Shares OutstandingADN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
ADN Yearly Total Debt VS Total AssetsADN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -63.77, we must say that ADN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ADN (-63.77) is worse than 95.65% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -63.77
ROIC/WACCN/A
WACC9.06%
ADN Yearly LT Debt VS Equity VS FCFADN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.06 indicates that ADN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.06, ADN is doing worse than 94.57% of the companies in the same industry.
A Quick Ratio of 0.05 indicates that ADN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.05, ADN is doing worse than 94.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.05
ADN Yearly Current Assets VS Current LiabilitesADN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.87% over the past year.
Looking at the last year, ADN shows a quite strong growth in Revenue. The Revenue has grown by 10.92% in the last year.
The Revenue has been growing by 67.03% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)48.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.19%
Revenue 1Y (TTM)10.92%
Revenue growth 3Y76.57%
Revenue growth 5Y67.03%
Sales Q2Q%-89.84%

3.2 Future

ADN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.75% yearly.
The Revenue is expected to grow by 633.14% on average over the next years. This is a very strong growth
EPS Next Y98.1%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2705.94%
Revenue Next 2Y633.14%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ADN Yearly Revenue VS EstimatesADN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADN Yearly EPS VS EstimatesADN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADN. In the last year negative earnings were reported.
ADN is valuated quite expensively with a Price/Forward Earnings ratio of 49.11.
Based on the Price/Forward Earnings ratio, ADN is valued a bit cheaper than the industry average as 69.57% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ADN to the average of the S&P500 Index (22.68), we can say ADN is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 49.11
ADN Price Earnings VS Forward Price EarningsADN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADN Per share dataADN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

ADN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADN's earnings are expected to grow with 44.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.75%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ADN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVENT TECHNOLOGIES HOLDINGS

NASDAQ:ADN (2/21/2025, 8:00:02 PM)

After market: 4.97 +0.01 (+0.2%)

4.96

-0.14 (-2.75%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryElectrical Equipment
Earnings (Last)11-25 2024-11-25
Earnings (Next)08-11 2025-08-11/amc
Inst Owners6.44%
Inst Owner Change-1.3%
Ins Owners9.21%
Ins Owner Change0%
Market Cap13.09M
Analysts45
Price TargetN/A
Short Float %5.76%
Short Ratio4.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 49.11
P/S 2.22
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-26.95
EYN/A
EPS(NY)0.1
Fwd EY2.04%
FCF(TTM)-4.03
FCFYN/A
OCF(TTM)-3.96
OCFYN/A
SpS2.23
BVpS-6.85
TBVpS-6.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -885.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.37%
ROA(5y)-96.93%
ROE(3y)-220.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.74%
Cap/Sales 2.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.05
Altman-Z -63.77
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)197.26%
Cap/Depr(5y)268.79%
Cap/Sales(3y)91.22%
Cap/Sales(5y)58.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.19%
EPS Next Y98.1%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.92%
Revenue growth 3Y76.57%
Revenue growth 5Y67.03%
Sales Q2Q%-89.84%
Revenue Next Year2705.94%
Revenue Next 2Y633.14%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.84%
OCF growth 3YN/A
OCF growth 5YN/A